Logo do repositório
 
Publicação

Effectiveness of the 2023 Autumn XBB.1.5 COVID-19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Study

2025-11-28Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorHumphreys, James
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorBraeye, Toon
dc.contributor.authorVan Evercooren, Izaak
dc.contributor.authorHansen, Christian Holm
dc.contributor.authorMoustsen-Helms, Ida Rask
dc.contributor.authorSacco, Chiara
dc.contributor.authorFabiani, Massimo
dc.contributor.authorCastilla, Jesús
dc.contributor.authorMartinez-Baz, Ivan
dc.contributor.authorMachado, Ausenda
dc.contributor.authorSoares, Patricia
dc.contributor.authorLjung, Rickard
dc.contributor.authorPihlstrom, Nicklas
dc.contributor.authorKissling, Esther
dc.contributor.authorNardone, Anthony
dc.contributor.authorMonge, Susana
dc.contributor.authorBacci, Sabrina
dc.contributor.authorNunes, Baltazar
dc.contributor.authorVEBIS-EHR Working Group
dc.date.accessioned2026-01-14T15:12:59Z
dc.date.available2026-01-14T15:12:59Z
dc.date.issued2025-11-28
dc.description.abstractBackground: After a period of low SARS- CoV-2 activity, viral circulation increased in Europe from May 2024, driven byimmune-evasive KP sublineages of the JN.1 variant. We estimated vaccine effectiveness (VE) of the XBB.1.5 dose administeredin autumn 2023 against COVID-19-related hospitalisations and deaths in individuals 65 years of age or older during this period. Methods: We conducted a multi-country cohort study across six EU nations in the VEBIS-EHR network using linked electronichealth records. VE against COVID-19-related hospitalisation and death during June–August 2024 was estimated using Cox re-gression in a two-stage analysis, adjusting for demographics, comorbidities and prior vaccination history. Results: Among individuals 65–79 and ≥ 80 years old, respectively, VE of the XBB.1.5 dose ≥ 6 months post administration was13% (95% CI: −12% to 33%) and 7% (95% CI: −7% to 19%) against hospitalisation and 39% (95% CI: −7% to 65%) and 3% (95% CI:−23% to 23%) against deaths. Conclusions: XBB.1.5 vaccination provided minimal residual protection against severe COVID-19 outcomes among adults aged≥ 65 years more than 6 months after vaccination, during the summer 2024 period of increased SARS- CoV-2 activity.eng
dc.description.sponsorshipAll the public health organisations involved received funding from the European Centre for Disease Prevention and Control (ECDC) Implementing Framework Contract ECDC/2021/018 ‘Vaccine effectiveness and impact of COVID-19 vaccines through routinely collected exposure and outcome using health registries’ (RS/2022/DTS/24104). In Portugal, this work was also supported by FCT—Fundação para a Ciência e Tecnologia, I.P. by project reference CEECINST/00049/2021/CP2817/CT0001 and DOI identifier https://doi.org/10.54499/CEECINST/00049/2021/CP2817/CT0001
dc.identifier.citationInfluenza Other Respir Viruses. 2025 Dec;19(12):e70198. doi: 10.1111/irv.70198
dc.identifier.doi10.1101/2025.04.30.25326709
dc.identifier.eissn1750-2659
dc.identifier.issn1750-2640
dc.identifier.pmid41312816
dc.identifier.urihttp://hdl.handle.net/10400.18/10692
dc.language.isoeng
dc.peerreviewedyes
dc.publisherWiley
dc.relationCEECINST/00049/2021/CP2817/CT0001
dc.relation.hasversionhttps://onlinelibrary.wiley.com/doi/10.1111/irv.70198
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCOVID-19
dc.subjectXBB.1.5
dc.subjectElectronic Health Records
dc.subjectVaccine Effectiveness
dc.subjectVEBIS
dc.subjectInfecções Respiratórias
dc.subjectEstados de Saúde e de Doença
dc.titleEffectiveness of the 2023 Autumn XBB.1.5 COVID-19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Studyeng
dc.typejournal article
dcterms.referenceshttps://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Firv.70198&file=Supplementary+material.docx
dspace.entity.typePublication
oaire.citation.issue12
oaire.citation.startPagee70198
oaire.citation.titleInfluenza and Other Respiratory Viruses
oaire.citation.volume19
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameMachado
person.familyNameSoares
person.familyNameNunes
person.givenNameAusenda
person.givenNamePatricia
person.givenNameBaltazar
person.identifier1050496
person.identifier.ciencia-id1217-6076-5D88
person.identifier.ciencia-id0415-632D-8609
person.identifier.ciencia-idAB11-AD48-A8DF
person.identifier.orcid0000-0002-1849-1499
person.identifier.orcid0000-0001-5033-9115
person.identifier.orcid0000-0001-6230-7209
person.identifier.scopus-author-id52063758300
person.identifier.scopus-author-id9133723200
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublicationdf1b8bab-1e35-4561-92d0-8aeb17371a29
relation.isAuthorOfPublicationbe4efa0d-49df-4a93-bfdd-b76d9f7bf492
relation.isAuthorOfPublication.latestForDiscovery544ad266-0c22-4a50-9ebc-86acc08d6666

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Influenza Resp Viruses - 2025 - Humphreys - Effectiveness of the 2023 Autumn XBB 1 5 COVID‐19 Booster During Summer 2024 in.pdf
Tamanho:
189.29 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DEP - Artigos em revistas internacionais
DDI - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais